| |
Non-diabetes
|
Diabetes
|
|---|
|
No CAD
|
Single vessel disease
|
Double vessel disease
|
Triple vessel disease
|
Diffuse disease
|
No CAD
|
Single vessel disease
|
Double vessel disease
|
Triple vessel disease
|
Diffuse disease
|
|---|
|
N (%)
|
56.922 (61.52)
|
13.627 (14.73)
|
6.409 (6.93)
|
7.022 (7.59)
|
8.542 (9.23)
|
13.134 (54.80)
|
3.320 (13.85)
|
2.111 (8.81)
|
2.997 (12.50)
|
2.407 (10.04)
|
|
Sex, male (%)
|
33.361 (58.61)
|
9.499 (69.71)
|
4.777 (74.54)
|
5.594 (79.66)
|
4.860 (56.90)
|
8.376 (63.77)
|
2.298 (69.22)
|
1.574 (74.56)
|
2.299 (76.71)
|
1.528 (63.48)
|
|
Age, mean (IQR*)
|
63.17 (55–72)
|
63.51 (55–72)
|
66.95 (59–75)
|
69.57 (63–77)
|
66.13 (59–74)
|
63.84 (57–72)
|
63.93 (57–72)
|
65.91 (59–73)
|
67.29 (61–74)
|
64.96 (58–72)
|
|
Smoking (%)
|
14.042 (24.67)
|
4.983 (36.57)
|
2.064 (32.20)
|
1.923 (27.39)
|
2.100 (24.58)
|
3.089 (23.52)
|
1.030 (31.02)
|
624 (29.56)
|
787 (26.26)
|
559 (23.22)
|
|
B-blockers* (%)
|
22.256 (39.10)
|
3.112 (22.84)
|
1.931 (30.13)
|
2.516 (35.83)
|
2.723 (31.88)
|
6.609 (50.32)
|
1.040 (31.33)
|
795 (37.66)
|
1.244 (41.51)
|
916 (38.06)
|
|
Statins (%)
|
22.529 (39.58)
|
3.360 (24.66)
|
2.078 (32.42)
|
2.771 (39.46)
|
2.981 (34.90)
|
8.515 (64.83)
|
1.462 (44.04)
|
1.011 (47.89)
|
1.611 (53.75)
|
1.332 (55.34)
|
|
ACE-I* (%)
|
18.914 (33.23)
|
3.076 (22.57)
|
1.817 (28.35)
|
2.277 (32.43)
|
2.632 (30.81)
|
8.008 (60.97)
|
1.470 (44.28)
|
985 (46.66)
|
1.600 (53.39)
|
1.307 (54.30)
|
|
Spironolacton (%)
|
2.314 (4.07)
|
250 (1.83)
|
179 (2.79)
|
225 (3.20)
|
296 (3.47)
|
1.048 (7.98)
|
125 (3.77)
|
103 (4.88)
|
188 (6.27)
|
158 (6.56)
|
|
Loop diuretics (%)
|
7.595 (13.34)
|
885 (6.49)
|
605 (9.44)
|
903 (12.86)
|
1.055 (12.35)
|
3.430 (26.12)
|
508 (15.30)
|
385 (18.24)
|
693 (23.12)
|
554 (23.02)
|
|
ASA* (%)
|
25.578 (44.94)
|
3.630 (26.64)
|
2.234 (34.86)
|
3.026 (43.09)
|
3.132 (36.67)
|
7.880 (60.00)
|
1.283 (38.64)
|
991 (46.94)
|
1.589 (53.02)
|
1.124 (46.70)
|
|
VKA* (%)
|
4.711 (8.28)
|
563 (4.13)
|
332 (5.18)
|
360 (5.13)
|
717 (8.39)
|
1.393 (10.61)
|
187 (5.63)
|
131 (6.21)
|
179 (5.97)
|
252 (10.47)
|
|
Platlet inhibitors (%)
|
26.598 (46.73)
|
3.849 (28.25)
|
2.371 (36.99)
|
3.208 (45.68)
|
3.346 (39.17)
|
8.187 (62.33)
|
1.374 (41.39)
|
1.042 (49.36)
|
1.690 (56.39)
|
1.207 (50.15)
|
|
Digoxin (%)
|
2.248 (3.95)
|
311 (2.28)
|
199 (3.11)
|
266 (3.79)
|
468 (5.48)
|
924 (7.04)
|
137 (4.13)
|
114 (5.40)
|
181 (6.04)
|
199 (8.27)
|
|
Atrial Fibrillation (%)
|
5.007 (8.80)
|
791 (5.80)
|
425 (6.63)
|
518 (7.38)
|
1.041 (12.19)
|
1.543 (11.75)
|
258 (7.77)
|
189 (8.95)
|
244 (8.14)
|
3.621 (15.04)
|
|
IHD* (%)
|
4.812 (8.45)
|
1.134 (8.32)
|
859 (13.40)
|
1.234 (17.57)
|
780 (9.13)
|
1.789 (13.62)
|
401 (12.08)
|
398 (18.85)
|
702 (23.42)
|
281 (11.67)
|
|
Renal Disease (%)
|
897 (1.58)
|
132 (0.97)
|
91 (1.42)
|
123 (1.75)
|
144 (1.69)
|
383 (2.92)
|
74 (2.23)
|
60 (2.84)
|
82 (2.74)
|
81 (3.37)
|
|
Hypertension (%)
|
9.099 (15.99)
|
1.772 (13.00)
|
1.029 (16.06)
|
1.290 (18.37)
|
1.877 (21.97)
|
4.115 (31.33)
|
871 (26.23)
|
599 (28.38)
|
932 (31.10)
|
916 (38.06)
|
|
Thromboembolus(%)
|
4.128 (7.25)
|
893 (6.55)
|
511 (7.97)
|
763 (10.87)
|
829 (9.70)
|
1.308 (9.96)
|
326 (9.82)
|
228 (10.80)
|
409 (13.65)
|
273 (11.34)
|
- Continuous variables are presented as means (with standard deviation values) and discrete variables as percentages (%). B-blocker Beta-blocker, ACEI Angiotensin converting enzyme inhibitors, ASA Acetylsalicylic acid, VKA Vitamin K antagonist
- *Beta-Blockers *Angiotensin Converting Enzyme Inhibitors *Acetylsalicylic Acid *Vitamin K Antagonists *Ischemic Heart Disease *Interquartile range
